Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Multiple Sclerosis: Update Bulletin [June 2016]

Product Code:
596200575
Publication Date:
June 2016
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in the multiple sclerosis (MS) treatment landscape. Topics covered include reactions to the Phase IIb/III MS-SPI/MS-ON trials of MedDay’s MD1003; the FDA approval of Biogen’s/AbbVie’s Zinbryta (daclizumab); TG Therapeutics’ Phase II study for ublituximab (TG-1101); as well as opinions on the top-line results from Biogen’s Phase II SYNERGY study, which is assessing the efficacy and safety of the anti-LINGO-1 mAb, opicinumab, in patients with relapsing forms of multiple sclerosis (RMS).

Key Questions Answered in this Update Bulletin:

  • What do KOLs think of the PhaseIIb/Phase III data for MD1003?
  • If approved, where would MD1003 be positioned in the treatment paradigm?
  • How have KOLs reacted to the FDA approval of Zinbryta?
  • Is there enthusiasm surrounding the initiation of a Phase II trial of ublituximab (TG-1101)?
  • How have KOLs reacted to opicinumab’s (anti-LINGO-1) Phase II SYNERGY trial data?



customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved